Seattle Genetics announced last month, during its first-quarter earnings report, that Laureate Pharma Inc. manufacture Seattle Genetics’ SGN-33 and SGN-70, experimental anti-cancer drugs entering the clinical trial stage. Here’s the original announcement: http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060425006119&newsLang=en.
Well, In-PharmaTechnologist.com now has a story with all the details about Laureate, which is based in Princeton, N.J. Read all about it here, http://www.in-pharmatechnologist.com/news/ng.asp?n=67875-laureate-pharma-seattle-genetics-sgn-sgn-monoclonal-antibodies. Laureate’s Web site also can be found here, http://www.laureatepharma.com/home.html.
*****
ICOS Corp., based just down the hill from Seattle Genetics in Bothell’s Canyon Park campus, went shopping today as it tries to boost the number of potential drug candidates in its development pipeline. The company struck a deal with Dyax Corp. of Cambridge, Mass., that gives ICOS access to Dyax’s library of antibodies and other intellectual property.
Even the investors who’ve been more optimistic about ICOS’ future than others have worried about the relatively short list of drugs in preclinical or clinical development by the company. The feeling is the company can’t count forever on earnings from Cialis or its active ingredient, tadalafil, which is being tested for a few other conditions. Read today’s raw press release about the deal with Dyax here: http://www.pharmalive.com/News/index.cfm?articleid=342949&categoryid=15. Dyax’s Web site is here: http://www.dyax.com/.
*****
One last thing … Eden Bioscience of Bothell saw its stock fall 39 percent just today amid heavy trading. No word on a potential trigger for the steep fall; a call this afternoon to Eden’s CFO wasn’t returned right away. Earlier this month, Eden announced one of its best quarters ever in terms of revenue. Combining the stock’s performance both Friday and today, Eden’s shares have fallen by more than half in just two days.
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.
